Clinical Trials

268 enrolled

Head and Neck Neoplasms

NCT07423078 2026-02-20

WOLF

87 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07290621 2026-02-06

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

30 enrolled

Phase 3 Not yet recruiting

Oropharyngeal Neoplasms

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT07110558 2025-08-07

PUPA

59 enrolled

Nasopharyngeal Carcinoma

NCT07088211 2025-07-31

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

39 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05147844 2025-07-14

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

NCT06228079 2025-07-04

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

176 enrolled

Nasopharyngeal Carcinoma

NCT06940180 2025-06-26

Toripalimab With Chemotherapy for Sinus Cancer

20 enrolled

Sinonasal undifferentiated carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Paranasal Sinus Neoplasms

NCT06235203 2025-06-03

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

154 enrolled

Nasopharyngeal Carcinoma

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

62 enrolled

Nasopharyngeal Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Nasopharyngeal Carcinoma

NCT06861712 2025-04-25

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

50 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Carcinoma

NCT06712888 2025-03-18

Navigation

466 enrolled

Nasopharyngeal Carcinoma

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

47 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

166 enrolled

Nasopharyngeal Carcinoma

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Phase 2 Completed

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

355 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT06323239 2024-08-20

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT06151743 2024-04-30

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

32 enrolled

Locally Advanced Hypopharyngeal Carcinoma

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

264 enrolled

Nasopharyngeal Carcinoma

NCT05773079 2024-04-01

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

28 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04473716 2023-11-22

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Phase 1 Completed

20 enrolled

Mouth Neoplasms

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

80 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06039631 2023-09-15

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

82 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

228 enrolled

Nasopharyngeal Carcinoma

NCT05993858 2023-08-15

PC-1

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04807140 2023-04-14

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05813626 2023-04-14

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

89 enrolled

Nasopharyngeal Carcinoma

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

45 enrolled

Nasopharyngeal Carcinoma

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Phase 1/2 Unknown

88 enrolled

Head and Neck Squamous Cell Cancer

NCT05628922 2022-11-29

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

198 enrolled

Nasopharyngeal Neoplasms

NCT05340491 2022-08-31

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

212 enrolled

Nasopharyngeal Carcinoma

NCT05484375 2022-08-02

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Nasopharyngeal Carcinoma

NCT05420597 2022-06-15

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

61 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT04073784 2022-04-26

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Phase 1 Unknown

41 enrolled

Nasopharyngeal Carcinoma

NCT05341193 2022-04-22

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 1/2 Unknown

32 enrolled

Nasopharyngeal Carcinoma

NCT04995120 2022-01-18

INSIGHT

42 enrolled

GastrointestinalHead & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase 1/2 Unknown

401 enrolled 1 FDA

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

NCT04992988 2021-08-20

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Nasopharyngeal Carcinoma

NCT04376866 2021-07-20

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

204 enrolled

Nasopharyngeal Carcinoma

NCT04947241 2021-07-01

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

Phase 1 Unknown

20 enrolled